Physician profile
Sharon Bode
NPI 1932179751
$4,926.29
in general payments reported to CMS, 2019-2025
25 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.52 · 2022: $420 · 2023: $1,050 · 2024: $1,968 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,056 · Travel and Lodging: $269 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,055.56 |
| Travel and Lodging | $268.85 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $945.65 | 2022-2024 | Watchman, Watchman Flx, Watchman Access System |
| Janssen Pharmaceuticals, INC | $833.59 | 2022-2025 | Xarelto, Opsumit, Uptravi |
| Amgen INC. | $506.89 | 2021-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $419.37 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Novo Nordisk INC | $321.55 | 2021-2025 | Ozempic, Wegovy |
| Impulse Dynamics (USA) INC. | $279.68 | 2023-2024 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $208.44 | 2023-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $205.22 | 2023-2025 | Opsumit, Uptravi |
| Abbott Laboratories | $191.44 | 2023-2025 | Mitraclip, Cardiomems |
| Astrazeneca Pharmaceuticals LP | $160.92 | 2022-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $134.68 | 2024-2025 | |
| Cvrx, INC. | $129.93 | 2023-2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $97.45 | 2024 | Inpefa |
| Heartflow, INC. | $77.73 | 2024-2025 | |
| Abiomed | $61.65 | 2023-2024 | Impella |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $57.10 | 2024-2025 | Lifevest |
| Scpharmaceuticals INC. | $52.35 | 2023-2025 | |
| Bridgebio Pharma, INC. | $49.69 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $49.06 | 2024 | Assure Wcd |
| Esperion Therapeutics, INC. | $31.35 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $29.23 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.82 | 2021 | |
| Dexcom, INC. | $22.24 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $17.65 | 2025 | |
| Merck Sharp & Dohme LLC | $17.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Bode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.